Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 17/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.32 |
| ▸ | DLK1 | P80370 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12614044 | 0.83 | VRK1 (0.31) | — | |
| SCHEMBL190709 | 0.76 | NUDT1 (0.32) | — | |
| SCHEMBL357802 | 0.76 | MAP3K12 (0.38) | MAP3K12PIK3CA | |
| SCHEMBL29952398 | 0.76 | MAP3K12 (0.38) | MAP3K12PIK3CA | |
| SCHEMBL454719 | 0.74 | MAPT (0.39) | PIK3CA | |
| SCHEMBL15201656 | 0.73 | TRPV4 (0.39) | PIK3CA | |
| SCHEMBL395314 | 0.73 | KDM4E (0.36) | — | |
| SCHEMBL2067107 | 0.73 | KDM4E (0.32) | — | |
| SCHEMBL16734984 | 0.72 | — | — | |
| SCHEMBL29092277 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008323-B2 | Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors | DOMAIN THERAPEUTICS (FR) | 2021-05-18 | — | — | US | disclosed |
| US-20180346468-A1 | SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2018-12-06 | — | — | US | disclosed |
| EP-3374360-A1 | SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | Mavalon Therapeutics Limited (GB) | 2018-09-19 | — | — | EP | disclosed |
| WO-2017081483-A1 | SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | MAVALON THERAPEUTICS LIMITED (GB) | 2017-05-18 | — | — | WO | disclosed |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346468-A1 | SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM3, GRM1, GRM2 | MAP3K12 1415/4885PIK3CA 1248/4885DLK1 2217/4885 |
| US-11008323-B2 | Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors | GRM3, GRM1, GRM2 | MAP3K12 1415/4885PIK3CA 1248/4885DLK1 2217/4885 |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | MAP3K12 89/4885PIK3CA 125/4885DLK1 1199/4885 |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | MAP3K12 89/4885PIK3CA 125/4885DLK1 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.